The role of sentinel lymph node biopsy in patients initially diagnosed with ductal carcinoma in situ resides in determining the predictors of invasive disease. The aim of the present study was to examine the incidence of sentinel lymph node metastases in a selected group of patients, with characteristics of high-risk ductal carcinoma in situ, in order to determine the clinical usefulness of sentinel lymph node biopsy.
Methods
A total of 90 patients with a biopsy diagnosis of ductal carcinoma in situ were treated. Fifty-two patients with high-risk ductal carcinoma in situ had sentinel lymph node biopsy. The following characteristics of the primary tumor were considered as indicative of a risk of invasive disease: presence of palpable mass, mammographic mass, multicentric disease that required mastectomy, and histologically high nuclear grade or non-high nuclear grade with necrosis. Subdermal injections of 99mTc-labeled human albumin and subareolar injection ofblue dye were used for sentinel lymph node identification. All sentinel nodes were sectioned serially and stained with hematoxylin and eosin. Immunohistochemical analysis was performed using a cytokeratin monoclonal antibody.
Results
A positive sentinel lymph node was found in only one patient (1.9%). The patient had a double lesion, and core-needle biopsy showed an atypical ductal hyperplasia and a intermediate degree of ductal carcinoma in situ. At pathologic review of the specimen, no invasive aspect was detected.
Conclusions
The results of our study indicate that sentinel lymph node metastasis in pure ductal carcinoma in situ is extremely uncommon. We therefore suggest that sentinel lymph node biopsy might be indicated for patients with ductal carcinoma in situ detected as a palpable mass or as large extensive microcalcifications, as well as for patients who are undergoing mastectomy, especially with immediate reconstruction.
GreenleeR.T., MurrayT., BoldenS., WingoP.A.: Cancer statistics 2000.CA Cancer J Clin, 50: 7–33, 2000.
2.
ErnsterV.L., BarclayJ., KerlikowskeK., WilkieH., Ballard-BarbashR.: Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program.Arch Intern Med, 160: 953–958, 2000.
3.
SilversteinM.J., GiersonE.D., ColburnW.J., RosserR.J., WaismanP., GamagamiP.: Axillary lymphadenectomy for intraductal carcinoma of the breast.Surg Gynecol Obstet, 172: 211–214, 1991.
4.
SilversteinM.J., SkinnerK.A., LomisT.J.: Predicting axillary nodal positivity in 2282 patients with breast carcinoma.Word J Surg, 25: 767–772, 2001.
5.
LymanG.H., GiulianoA.E., SomerfieldM.R., BensonAB3rd, BodurkaD.C., BursteinH.J., CochranA.J., CodyHS3rd, EdgeS.B., GalperS., HaymanJ.A., KimT.Y., PerkinsC.L., PodoloffD.A., SivasubramaniamV.H., TurnerR.R., WahlR., WeaverD.L., WolffA.C., WinerE.P.: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer.J Clin Oncol, 23: 7703–7720, 2005.
6.
CoxC.E., NguyenK., GrayR.J., SaludC., KuN.N., DupontE., HutsonL., PeltzE., WhiteheadG., ReintgenD., CantorA.: Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS?Am Surg, 67: 513–521, 2001.
7.
LibermanL.: Percutaneous imaging-guided core breast biopsy: state of the art at the millennium.Am J Roentgenol, 174: 1191–1199, 2000.
8.
JackmanR.J., BurbankF., ParkerS.H., EvansWP3rd, LechnerM.C., RichardsonT.R., SmidA.A., BorofskyH.B., LeeC.H., GoldsteinH.M., SchillingK.J., WrayA.B., BremR.F., HelbichT.H., LehrerD.E., AdlerS.J.: Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates.Radiology, 218: 497–502, 2001.
9.
WonB., ReynoldsH.E., LazaridisL., JacksonV.P.: Stereotactic biopsy of ductal carcinoma in situ of the breast using an 11-gauge vacuum-assisted device: persistent underestimation of disease.Am J Roentgenol, 173: 227–229, 1999.
10.
BurbankF.: Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy.Radiology, 202: 843–847, 1997.
11.
SilversteinM.J., WaismanJ.R., GamagamiP., GiersonE.D., ColburnW.J., RosserR.J., GordonP.S., LewinskyB.S., FingerhutA.: Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice.Cancer, 66: 102–108, 1990.
12.
Klauber-DeMoreN., TanL.K., LibermanL., KaptainS., FeyJ., BorgenP., HeerdtA., MontgomeryL., PagliaM., PetrekJ.A., CodyH.S., Van ZeeK.J.: Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma in-situ and ductal carcinoma in-situ with microinvasion?Ann Surg Oncol, 7: 636–642, 2000.
13.
D'Eredita’G., GiardinaC., GuerrieriA.M., BerardiT.: A further validation of subareolar injection technique for breast sentinel lymph node biopsy.Ann Surg Oncol, 13: 701–707, 2006.
14.
D'Eredita’G., GiardinaC., IngravalloG., RubiniG., LattanzioV., BerardiT.: Sentinel lymph node biopsy in multiple breast cancer using subareolar injection of the tracer.Breast, 16: 316–322, 2007.
15.
KernK.A.: Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye.J Am Coll Surg, 189: 539–545, 1999.
16.
VialeG., MaioranoE., MazzarolG., ZurridaS., GalimbertiV., LuiniA., RenneG., PruneriG., MaisonneuveP., VeronesiU.: Histologic detection and clinical implications of micrometastases in axillary lymph nodes for patients with breast carcinoma.Cancer, 92: 1378–1384, 2001.
17.
IntraM., VeronesiP., MazzarolG., GalimbertiV., LuiniA., SacchiniV., TrifiròG., GentiliniO., PruneriG., NaninatoP., TorresF., PaganelliG., VialeG., VeronesiU.: Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast.Arch Surg, 138: 309–313, 2003.
18.
YenT.W., HuntK.K., RossM.I., MirzaN.Q., BabieraG.V., Meric-BernstamF., SingletaryS.E., SymmansW.F., GiordanoS.H., FeigB.W., AmesF.C., KuererH.M.: Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.J Am Coll Surg, 200: 516–526, 2005.
19.
KatzA., GageI., EvansS., ShafferM., FleuryT., SmithF.P., FlaxR., DrogulaC., PetrucciP., MagnantC.: Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer.Am J Surg, 191: 761–766, 2006.
20.
MooreK.H., SweeneyK.J., WilsonM.E., GoldbergJ.I., BuchananC.L., TanL.K., LibermanL., TurnerR.R., LagiosM.D., CodyH.S.III, GiulianoA.E., SilversteinM.J., Van ZeeK.J.: Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.Ann Surg Oncol, 14: 2911–2917, 2007.
21.
LagiosM.D., WestdahlP.R., MargolinF.R., RoseM.R.: Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures.Cancer, 50: 1309–1314, 1982.
TamhaneR., DahlstromJ.E., McCallumD.D., BuckinghamJ.M.: The clinical significance of cytokeratin-positive cells in lymph nodes at the time of mastectomy from patients with ductal carcinoma-in-situ.Ann Surg Oncol, 9: 999–1003, 2002.
24.
CarterB.A., JensenR.A., SimpsonJ.F., PageD.L.: Benign transport of breast epithelium into axillary lymph nodes after biopsy.Am J Clin Pathol, 113: 259–265, 2000.
25.
DiazN.M., CoxC.E., EbertM., ClarkJ.D., VrcelV., StowellN., SharmaA., JakubJ.W., CantorA., CentenoB.A., DupontE., Muro-CachoC., NicosiaS.: Benign mechanical transport of breast epithelial cells to sentinel lymph nodes.Am J Surg Pathol, 28: 1641–1645, 2004.
26.
IntraM., RotmenszN., VeronesiP., ColleoniM., IodiceS., PaganelliG., VialeG., VeronesiU.: Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast. The experience of the European Institute of Oncology on 854 patients in 10 years.Ann Surg, 247: 315–319, 2008.
27.
GoyalA., Douglas-JonesA., MonypennyI., SweetlandH., StevensG., ManselR.E.: Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases.Breast Cancer Res Treat, 98: 311–314, 2006.
28.
MoranC.J., KellM.R., FlanaganF.L., KennedyM., GoreyT.F., KerinM.J.: Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients.Am J Surg, 194: 172–175, 2007.
29.
SakrR., AntoineM., BarrangerE., DubernardG., SalemC., DaraïE., UzanS.: Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma.Breast J, 14: 55–60, 2008.
30.
ZavagnoG., CarcoforoP., MarconatoR., FranchiniZ., ScalcoG., BurelliP., PietrarotaP., LiseM., MencarelliR., CapitanioG., BallarinA., PierobonM.E., MarconatoG., NittiD.: Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast.BMC Cancer, 5: 28, 2005.
31.
El-TamerM., ChunJ., GillM., BassiD., LeeS., HibshooshH., MansukhaniM.: Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ.Ann Surg Oncol, 12: 254–259, 2005.
